Novel membrane-tube type glaucoma shunt device for glaucoma surgery

Area of Science:

• Ophthalmology
• Surgical Innovation
• Glaucoma Management

Background:

• Conventional glaucoma surgery, such as trabeculectomy, presents challenges in achieving predictable intraocular pressure (IOP) control.
• A novel membrane-tube (MT) glaucoma shunt device, MicroMT, was developed to enhance surgical safety and IOP management.
• The MicroMT aims to provide a more reliable alternative for patients with insufficient IOP control despite medical therapy.

Purpose of the Study:

• To introduce the surgical technique and evaluate the outcomes of the novel MicroMT glaucoma shunt.
• To assess the safety and efficacy of the MicroMT device in reducing intraocular pressure (IOP).
• To compare the MicroMT device's performance against conventional glaucoma surgical methods.

Main Methods:

• A retrospective, non-comparative, interventional case series was conducted.
• The MicroMT device was implanted in 43 eyes of patients with medically uncontrolled glaucoma.
• The MicroMT features an expanded polytetrafluoroethylene membrane and a silicone tube with an adjustable intraluminal stent for controlled aqueous drainage.

Main Results:

• Mean IOP significantly decreased from 22.5 mmHg preoperatively to 11.1 mmHg at 3 years post-implantation (50.7% reduction; P < 0.01).
• Intraluminal stent removal at 4 weeks post-operation led to an additional 40.2% IOP reduction (P < 0.01).
• The 3-year success rate (IOP 6-21 mmHg, ≥20% reduction) was 89.5%, with no instances of postoperative ocular hypotony or device-related complications.

Conclusions:

• MicroMT implantation offers a safe and effective novel therapy for reducing intraocular pressure (IOP) in glaucoma patients.
• The device demonstrates a low risk of postoperative ocular hypotony, a common complication of traditional glaucoma surgery.
• Glaucoma surgery utilizing the MicroMT device presents a viable and potentially superior alternative to conventional surgical interventions.